期刊文献+

人干细胞因子受体膜外区1~3免疫球蛋白样结构域的表达、纯化及活性 被引量:2

Expression,Purification,and Characterization of the First Three Immunoglobulin-like Domains of Human Stem Cell Factor Receptor
下载PDF
导出
摘要 目的 在原核和真核细胞中表达人干细胞因子受体(c-Kit)配体结合区膜外N端1~3免疫球蛋白样结构域(c-Kit/Ig1~3),研究其配体结合活性.方法 采用重叠延伸PCR定点诱变法合成c-Kit/Ig1~3双突变片段(c-Kit/Ig1~3DM),构建pET16b-c-Kit/Ig1~3DM表达质粒,转化E.coli BL21(DE3)诱导表达,稀释复性,镍柱纯化.将C端添加组氨酸标签的c-Kit/Ig1~3基因克隆入真核表达载体pEAK12中,转染HEK293 ET细胞构建c-kit/Ig1~3高效表达细胞株,从细胞培养上清中使用镍金属螯合柱收集纯化蛋白.His-tag pull-down和酶联免疫结合实验检测融合蛋白配体结合活性.结果 在大肠杆菌中c-Kit/Ig1~3^DM以包涵体形式表达,复性后配体结合活性很低.在HEK293 ET细胞中筛选到2个高效表达c-Kit/Ig1~3的细胞株,上清表达量为2μg/ml,融合蛋白相对分子质量为58 000;受体配体结合实验显示真核表达的c-Kit/Ig1~3有明显的干细胞因子特异结合活性,解离常数Kd值为9.39 nmol/L.结论获得了具有较高配体结合活性的c-Kit/Ig1~3融合蛋白. Objective To express the first three immunoglobulin-like domains of human stem cell factor receptor ( c-Kit/Ig1-3 ) in E. coli and HEK293 ET cells and study their binding activity for stem cell factor (SCF). Methods In prokaryotic expression system, a double mutant form of c-Kit/Ig1-3 ( c-Kit/Ig1- 3^DM) was produced by overlap PCR and cloned into pET16b. The recombinant protein was expressed in E. coli BL21 (DE3) and refolded by dilution. In eukaryotic expression system, the gene of c-Kit/Ig1-3 with eight histidine segments was cloned into pEAK12 and the recombinant plasmid was transfected into HEK293 ET cells. The fusion protein was harvested from the growth medium and purified on Ni-NTA agarose column. The recombinant protein was tested for the receptor binding activity with his-tag pull-down and enzyme-linked immunosorbent binding assay. Results In E. coli c-Kit/Ig1-3^DM was produced as an inclusion body and showed low binding activity for SCF after refolding. Two HEK293 ET cell clones that express high levels of c-Kit/Ig1-3 were produced and each clone secreted 2μg/ml of recombinant protein, whose relative molecular mass was about 58 000. Eukaryotically expressed c-Kit/Ig1-3 had specific binding activity for SCF, and the dissociation constant(Kd) was 9.39 nmoL/L Conclusion c-Kit/Ig1-3 with high receptor binding activity is successfully produced in HEK293 ET cells.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2006年第2期154-158,共5页 Acta Academiae Medicinae Sinicae
基金 国家高技术发展计划(863)重大专项基金(2003AAZ3360)~~
关键词 人干细胞因子受体 免疫球蛋白样结构域 HIS-TAG pull-down 酶联免疫结合实验 human stem cell factor receptor immunoglobulin-like domains his-tag pull-down enzyme-linked immunosorbent binding assay
  • 相关文献

参考文献12

  • 1Blechman JM,Lev S,Brizzi MF,et al.Soluble c-kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor.J Biol Chem,1993,268 (6):4399-4406.
  • 2Dahlen DD,Lin NL,Liu YC,et al.Soluble Kit receptor blocks stem cell factor bioactivity in vitro.Leuk Res,2001,25(5):413-421.
  • 3Nakamura Y,Tajima F,Ishiga K,et al.Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice.Exp Hematol,2004,32(4):390-396.
  • 4Takeshima H,Kuratsu J.A review of soluble c-kit (s-kit) as a novel tumor marker and possible molecular target for the treatment of CNS germinoma.Surg Neurol,2003,60 (4):321-324.
  • 5李川晟,程涛,许燕群.重组人干细胞因子对放射病患者造血细胞的体外作用[J].中华放射医学与防护杂志,1994,14(4):221-224. 被引量:8
  • 6王亚栋,张艳丽,杨克恭,邓艳春,苏林,罗丝,刘长征,陈松森.携带人FL、GM-CSF基因的裸DNA的抑瘤作用[J].基础医学与临床,2005,25(10):914-919. 被引量:2
  • 7Novokhatny V,Medved L,Lijnen HR,et al.Tissue-type plasminogen activator (tPA) interacts with urokinase-type plasminogen activator (uPA) via tPA's lysine binding site.An explanation of the poor fibrin affinity of recombinant tPA/uPA chimeric molecules.J Biol Chem,1995,270(15):8680-8685.
  • 8Ishibashi M,Tokunaga H,Arakawa T,et al.Expression,purification,and characterization of the active immunoglobulinlike domain of human granulocyte-colony-stimulating factor receptor in Escherichia coli.Protein Expr Purif,2001,21 (2):317-322.
  • 9Singh SM,Panda AK.Solubilization and refolding of bacterial inclusion body proteins.J Biosci Bioeng,2005,99 (4):303-310.
  • 10Jungbauer A,Kaar W,Schlegl R.Folding and refolding of proteins in chromatographic beds.Curr Opin Biotechnol,2004,15(5):487-494.

二级参考文献10

  • 1Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells[J]. Cell, 1993, 75(6):1157-1167.
  • 2Maraskovsky E, Pulendran B, Brasel K, et al. Dramatic numerical increase of functionally mature dendritic cells in hFLT3 ligand-treated mice[J]. Adv Exp Med Biol, 1997,417: 33-40.
  • 3Daro E, Butz E, Smith J, et al. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand, GM-CSF and Flt3 ligand plus GM-CSF[J]. Cytokine,2002,17(3):119 - 130.
  • 4Ferreira GN, Monteiro GA, Prazeres DM, et al. Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications[J]. Trends Biotechnol, 2000,18(9): 380 - 388.
  • 5Prazeres DM, Ferreira GN, Monteiro GA, et al. Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks[J]. Trends Biotechnol, 1999, 17(4): 169 - 174.
  • 6Sambrook J, Russell DW. Molecular Cloning: a laboratory manual[M]. 3rd ed. New York: Cold Spring Harbor Laboratory Press, 2001. A8.52-A8.55.
  • 7Lu QL, Bou-Gharios G, Partridge TA. Non-viral gene delivery in skeletal muscle: a protein factory[J]. Gene Ther,2003, 10(2):131-142.
  • 8Peron JM, Esche C, Subbotin VM, et al. FL33-1igand administration inhibits liver metastases: role of NK cells[J]. J Immunol, 1998,161(11):6164 - 6170.
  • 9张友鸿,周希亚,陈松森,娄可佳,刘深基,杨克恭,何维.人FL在大肠杆菌中的表达及表达产物的纯化和生物学活性测定[J].基础医学与临床,2002,22(2):125-129. 被引量:1
  • 10马大龙.基因治疗的新型载体研究进展[J].基础医学与临床,2002,22(6):504-507. 被引量:11

共引文献8

同被引文献30

  • 1张力群,王清明,范国才,陈吉中,陈惠鹏.具有GCSF活性的噬菌体展示肽[J].中国生物化学与分子生物学报,2004,20(6):768-772. 被引量:1
  • 2李川晟,程涛,许燕群.重组人干细胞因子对放射病患者造血细胞的体外作用[J].中华放射医学与防护杂志,1994,14(4):221-224. 被引量:8
  • 3Broudv V C. Stem cell factor and hematopoiesis. Blood, 1997, 90 : 1345 -1364.
  • 4Ashman I. K. The biology of stem cell factor and its receptor c- kit. Int J Biochem Cell& Boil,1999, 31:1037-1051.
  • 5Yazawa S, Opatowsky Y, Zhang Z, et al. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell, 2007, 130:213-215.
  • 6Glaspy J, Davis M W , Parker W R L. Biology and clinical potential of stem cell factor. Canncer Chemother Pharrncol, 1996, 38(suppl) :553 -557.
  • 7Glaiy J A, Shpall E T, Lemaistre C F, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in high-risk breat cancer patients. Blood, 1997, 90 : 2939-2943.
  • 8Xiang F L, Lu X, Hammoud L, et al. Cardiomyocyte-specific overcxpression of human stem cell improves cardiac function and survival after myocardial infarction in mice. Circulation, 2009, 120:1065 -1074.
  • 9Basset R L, Begley C G , Maher D, et al. Rapid hematoietic recovery after multicycle high-dose chemotherapy : enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem cell factor. J Clin Oncol, 1998,16(5) :1899-1908.
  • 10Shpall E J, Wheeler C A, Turner S A. A randomsed phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood, 1999,93(8) :2491-2501.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部